Announcements Trials

Browse Landscape

Phase

Phase 3 1 Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Melanoma 106 Carcinoma, Non-Small-Cell Lung 34 Carcinoma, Renal Cell 23 Prostatic Neoplasms 17 Neoplasms 15 Brain Neoplasms 15 Neoplasm Metastasis 14 Lung Neoplasms 12 Breast Neoplasms 11 Uveal Melanoma 10 Pancreatic Neoplasms 10 Sarcoma 9 Small Cell Lung Carcinoma 7 Urinary Bladder Neoplasms 6 Squamous Cell Carcinoma of Head and Neck 6 Kidney Neoplasms 6 Diabetes Mellitus, Insulin-Dependent, 12 6 Carcinoma, Transitional Cell 6 Carcinoma, Hepatocellular 6 Skin Neoplasms 5 Ovarian Neoplasms 5 Histiocytoma, Malignant Fibrous 5 Colorectal Neoplasms 5 Uterine Cervical Neoplasms 4 Triple Negative Breast Neoplasms 4 Recurrence 4 Neuroendocrine Tumors 4 Mesothelioma 4 Glioblastoma 4 Colonic Neoplasms 4

Interventions

Nivolumab 2 Ipilimumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Various Advanced Cancer × Ipilimumab × Clear all

NCT03130959 2022-08-09

CheckMate 908

Bristol-Myers Squibb

Phase 2 Completed

166 enrolled 33 charts

Various Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡